Article

OSI, Eyetech complete $935 million merger

Melville, NY—OSI Pharmaceuticals has completed its $935 million acquisition of Eyetech Pharmaceuticals Inc. after reviewing recent data by Eyetech competitor Genentech Inc.

Melville, NY-OSI Pharmaceuticals has completed its $935 million acquisition of Eyetech Pharmaceuticals Inc. after reviewing recent data by Eyetech competitor Genentech Inc.

The deal, which was finalized Nov. 14, did not help OSI's stock price, which continued to fall from $30.35 per share on Nov. 10 to $24.62 on Nov. 18. OSI stock price, at a high of $41.03 before the Aug. 21 merger announcement, has never recovered. Meanwhile, Eyetech shares rose $1.57 to $18.19 in mid-day trading on Nov. 14.

OSI shareholders have been concerned about Genentech's ranibizumab (Lucentis) drug, which could compete with Eyetech's pegaptanib sodium (Macugen) as a treatment for age-related macular degeneration. Analysts also expressed concern about the future of OSI's relationship with Genentech, which also collaborates with OSI on erlotinib (Tarceva), a cancer drug.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.